Prenatal Screening Tests Devices Market is predicted to reach USD 2 billion at a CAGR of 12.00% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Prenatal Screening Tests Devices Market”.

The Prenatal Screening Tests Devices market is estimated to register a CAGR of 12.00% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global Prenatal Screening Tests Devices market— Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, Agilent Technologies Inc, Roche Diagnostics International Ltd, PerkinElmer Inc, Beckman Coulter Inc, Abbott Laboratories, Siemens Healthineers AG, Quidel Corp, Thermo Fisher Scientific Inc, Tosoh Corp

Global Prenatal Screening Tests Devices Market Highlights

The global Prenatal Screening Tests Devices market is accounted to register a CAGR of 12.00% during the forecast period and is estimated to reach USD 2 billion by 2032.

Delaying childbirth has been linked to an increased risk of chromosomal abnormalities and genetic diseases in infants. Prenatal screening tests to identify these anomalies are becoming more and more necessary as more women want to become pregnant at older ages. Spending more on healthcare, particularly in developed and developing nations, helps to enhance access to screening tests and prenatal care, which in turn promotes market expansion. However, due to high costs or inadequate healthcare infrastructure, access to advanced prenatal screening tests may be restricted in some areas or healthcare settings, which could have an impact on their general adoption.

Access full details: Prenatal Screening Tests Devices Market Research Report 

Segment Analysis

The global Prenatal Screening Tests Devices market has been segmented based on test.

On the basis of test, the market is segmented into Alpha-Fetoprotein (AFP) Tests, Free Beta Human Chorionic Gonadotropin (hCG) Tests, Inhibin A Tests, Non-invasive prenatal testing (NIPT), Pregnancy Associated Plasma Protein A (PAPP-A) Tests, Total Human Chorionic Gonadotropin (hCG) Tests, Unconjugated Estriol (uE3) Tests. The non-invasive prenatal testing (NIPT) segment was attributed to holding the largest market share in 2022. Because a blood test called NIPT is more precise than the initial pregnancy screening exam.

Regional Analysis

The global Prenatal Screening Tests Devices market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Prenatal Screening Tests Devices market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Prenatal Screening Tests Devices market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Prenatal Screening Tests Devices market comprises of Middle East, Africa, and Latin America.

The largest market share for Prenatal Screening Tests Devices was maintained by the North American regional sector. Prenatal screening procedures have become more precise, effective, and non-invasive as a result of ongoing technological breakthroughs, notably in the fields of genetic testing and molecular diagnostics. These developments in technology propel the market's expansion. The need for screening tools and tests is fueled by growing awareness among expectant parents and medical professionals of the value of prenatal screening for early detection of fetal abnormalities. Pregnant women in North America are encouraged to use screening tests widely by supportive government regulations, programs that promote prenatal care, and prenatal testing coverage provided by health insurance.

Moreover, the Europe market has been persistently growing over the forecast period. Europe is renowned for its state-of-the-art medical facilities, sophisticated healthcare systems, and easy access to cutting-edge technologies. Prenatal screening tests are widely accessible and widely used thanks to this infrastructure. Preventive medicine and early disease detection are the main priorities of European healthcare systems. This strategy is in line with prenatal screening tests, which help to promote their adoption by making it easier to identify fetal anomalies early on.

Additionally, Like in other industrialized nations, women in some parts of Asia Pacific are delaying giving birth more frequently, which increases the chance that newborns will have genetic problems. The need for prenatal screening tests among older pregnant moms is being driven by this trend. The population of the Asia Pacific area is substantial, and its birth rate is strong. There is a significant need for prenatal screening tests to identify genetic illnesses and fetal anomalies as a result of this demographic trend.

Furthermore, the rest of the world's Prenatal Screening Tests Devices market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's rising investment research and development. Government support, a rise in investor interest, and the viability of the technology in the sector are all contributing factors to the market expansion.

Key Findings of the Study

• The global Prenatal Screening Tests Devices market is expected to reach USD 2 billion by 2032, at a CAGR of 12.00% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market Because there is a significant need for prenatal screening tests to identify genetic illnesses and fetal anomalies as a result of this demographic trend.


• Based on test, the non-invasive prenatal testing (NIPT) segment was attributed to holding the largest market in 2022.


• Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, Agilent Technologies Inc, Roche Diagnostics International Ltd, PerkinElmer Inc, Beckman Coulter Inc, Abbott Laboratories, Siemens Healthineers AG, Quidel Corp, Thermo Fisher Scientific Inc, Tosoh Corp.